Literature DB >> 23494230

Multiple nicotine training doses in mice as a basis for differentiating the effects of smoking cessation aids.

Colin S Cunningham1, Lance R McMahon.   

Abstract

RATIONALE: Receptor mechanisms underlying the behavioral effects of clinically used nicotinic acetylcholine receptor agonists have not been fully established.
OBJECTIVE: Drug discrimination was used to compare receptor mechanisms underlying the effects of smoking cessation aids.
METHODS: Separate groups of male C57BL/6J mice discriminated 0.56, 1, or 1.78 mg/kg of nicotine base. Nicotine, varenicline, and cytisine were administered alone, in combination with each other, and in combination with mecamylamine and dihydro-β-erythroidine (DHβE). Midazolam and morphine were tested to examine sensitivity to non-nicotinics.
RESULTS: The ED50 value of nicotine to produce discriminative stimulus effects systematically increased as training dose increased. Varenicline and cytisine did not fully substitute for nicotine and, as compared with nicotine, their ED50 values varied less systematically as a function of nicotine training dose. Morphine did not substitute for nicotine, whereas midazolam substituted for the low and not the higher training doses of nicotine. As training dose increased, the dose of mecamylamine needed to produce a significant rightward shift in the nicotine dose-effect function also increased. DHβE antagonized nicotine in animals discriminating the smallest dose of nicotine. Varenicline did not antagonize the effects of nicotine, whereas cytisine produced a modest though significant antagonism of nicotine.
CONCLUSIONS: These results suggest that differences in pharmacologic mechanism between nicotine, varenicline, and cytisine include not only differences in efficacy at a common subtype of nicotinic acetylcholine receptor, but also differential affinity and/or efficacy at multiple receptor subtypes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23494230      PMCID: PMC3695008          DOI: 10.1007/s00213-013-3037-5

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  28 in total

1.  Structural differences determine the relative selectivity of nicotinic compounds for native alpha 4 beta 2*-, alpha 6 beta 2*-, alpha 3 beta 4*- and alpha 7-nicotine acetylcholine receptors.

Authors:  Sharon R Grady; Ryan M Drenan; Scott R Breining; Daniel Yohannes; Charles R Wageman; Nikolai B Fedorov; Sheri McKinney; Paul Whiteaker; Merouane Bencherif; Henry A Lester; Michael J Marks
Journal:  Neuropharmacology       Date:  2010-01-28       Impact factor: 5.250

2.  Ligands selective for alpha4beta2 but not alpha3beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat.

Authors:  Janice W Smith; Adrian Mogg; Elisiana Tafi; Eleanor Peacey; Ian A Pullar; Philip Szekeres; Mark Tricklebank
Journal:  Psychopharmacology (Berl)       Date:  2006-11-18       Impact factor: 4.530

3.  Acute and chronic tolerance to nicotine measured by activity in rats.

Authors:  I P Stolerman; R Fink; M E Jarvik
Journal:  Psychopharmacologia       Date:  1973-06-29

4.  Nicotinic acetylcholine receptors in the mesolimbic pathway: primary role of ventral tegmental area alpha6beta2* receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement.

Authors:  Cecilia Gotti; Stefania Guiducci; Vincenzo Tedesco; Silvia Corbioli; Lara Zanetti; Milena Moretti; Alessio Zanardi; Roberto Rimondini; Manolo Mugnaini; Francesco Clementi; Christian Chiamulera; Michele Zoli
Journal:  J Neurosci       Date:  2010-04-14       Impact factor: 6.167

5.  Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.

Authors:  Jotham W Coe; Paige R Brooks; Michael G Vetelino; Michael C Wirtz; Eric P Arnold; Jianhua Huang; Steven B Sands; Thomas I Davis; Lorraine A Lebel; Carol B Fox; Alka Shrikhande; James H Heym; Eric Schaeffer; Hans Rollema; Yi Lu; Robert S Mansbach; Leslie K Chambers; Charles C Rovetti; David W Schulz; F David Tingley; Brian T O'Neill
Journal:  J Med Chem       Date:  2005-05-19       Impact factor: 7.446

6.  Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline.

Authors:  C Reavill; B Walther; I P Stolerman; B Testa
Journal:  Neuropharmacology       Date:  1990-07       Impact factor: 5.250

7.  Discriminative stimulus (DS) properties of nicotine in the C57BL/6 mouse.

Authors:  S A Varvel; J R James; S Bowen; J A Rosecrans; L D Karan
Journal:  Pharmacol Biochem Behav       Date:  1999-05       Impact factor: 3.533

8.  Antagonism of the discriminative and aversive stimulus properties of nicotine in C57BL/6J mice.

Authors:  J Gommans; I P Stolerman; M Shoaib
Journal:  Neuropharmacology       Date:  2000-10       Impact factor: 5.250

9.  The role of nicotinic receptor beta-2 subunits in nicotine discrimination and conditioned taste aversion.

Authors:  M Shoaib; J Gommans; A Morley; I P Stolerman; R Grailhe; J-P Changeux
Journal:  Neuropharmacology       Date:  2002-03       Impact factor: 5.250

10.  Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.

Authors:  H Rollema; L K Chambers; J W Coe; J Glowa; R S Hurst; L A Lebel; Y Lu; R S Mansbach; R J Mather; C C Rovetti; S B Sands; E Schaeffer; D W Schulz; F D Tingley; K E Williams
Journal:  Neuropharmacology       Date:  2006-12-08       Impact factor: 5.250

View more
  12 in total

1.  Differential antagonism and tolerance/cross-tolerance among nicotinic acetylcholine receptor agonists: scheduled-controlled responding and hypothermia in C57BL/6J mice.

Authors:  Fernando B de Moura; Lance R McMahon
Journal:  Behav Pharmacol       Date:  2016-04       Impact factor: 2.293

2.  Delivery of nicotine aerosol to mice via a modified electronic cigarette device.

Authors:  Timothy W Lefever; Youn O K Lee; Alexander L Kovach; Melanie A R Silinski; Julie A Marusich; Brian F Thomas; Jenny L Wiley
Journal:  Drug Alcohol Depend       Date:  2017-01-18       Impact factor: 4.492

3.  Route of administration effects on nicotine discrimination in female and male mice.

Authors:  Timothy W Lefever; Brian F Thomas; Alexander L Kovach; Rodney W Snyder; Jenny L Wiley
Journal:  Drug Alcohol Depend       Date:  2019-08-24       Impact factor: 4.492

4.  Effects of long-term smoking on the activity and mRNA expression of CYP isozymes in rats.

Authors:  Xiao-Meng He; Ying Zhou; Ming-Zhen Xu; Yang Li; Hu-Qun Li; Wei-Yong Li
Journal:  J Thorac Dis       Date:  2015-10       Impact factor: 2.895

5.  Ultrapotent chemogenetics for research and potential clinical applications.

Authors:  Christopher J Magnus; Peter H Lee; Jordi Bonaventura; Roland Zemla; Juan L Gomez; Melissa H Ramirez; Xing Hu; Adriana Galvan; Jayeeta Basu; Michael Michaelides; Scott M Sternson
Journal:  Science       Date:  2019-03-14       Impact factor: 47.728

6.  The contribution of α4β2 and non-α4β2 nicotinic acetylcholine receptors to the discriminative stimulus effects of nicotine and varenicline in mice.

Authors:  Fernando B de Moura; Lance R McMahon
Journal:  Psychopharmacology (Berl)       Date:  2016-12-27       Impact factor: 4.530

7.  Attenuated nicotine-like effects of varenicline but not other nicotinic ACh receptor agonists in monkeys receiving nicotine daily.

Authors:  Colin S Cunningham; Megan J Moerke; Martin A Javors; F Ivy Carroll; Lance R McMahon
Journal:  Br J Pharmacol       Date:  2016-11-06       Impact factor: 8.739

8.  Discriminative stimulus and hypothermic effects of some derivatives of the nAChR agonist epibatidine in mice.

Authors:  Jesse S Rodriguez; Colin S Cunningham; Fernando B Moura; Pauline Ondachi; F Ivy Carroll; Lance R McMahon
Journal:  Psychopharmacology (Berl)       Date:  2014-05-07       Impact factor: 4.530

Review 9.  More than Smoke and Patches: The Quest for Pharmacotherapies to Treat Tobacco Use Disorder.

Authors:  M J Moerke; L R McMahon; J L Wilkerson
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

10.  Rapid nicotine tolerance and cross-tolerance to varenicline in rhesus monkeys: Drug discrimination.

Authors:  Megan J Moerke; Lance R McMahon
Journal:  Exp Clin Psychopharmacol       Date:  2018-08-13       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.